What is VKTX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 3.63B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VKTX?

P/E (TTM) is n/a and 52-week range is $25.77 to $43.15 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VKTX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VKTX?

The company profile lists net income (TTM) near $-544M, EPS (TTM) near $-4.66 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Viking Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 116.7M shares outstanding, ISIN US92686J1060 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Viking Therapeutics Inc

$VKTX

Health Care · Biotechnology

IR Run Scenarios

$28.51

+2.81%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 59 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Employees

Website

vikingtherapeutics.com/

IPO

2015-04-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)